Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2022 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)...
February 03, 2022 16:01 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs

Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023 12-week data from Phase 2a study of UBX1325 in diabetic macular edema (DME) expected mid-2022...
February 02, 2022 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
January 04, 2022 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022

12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular degeneration (wet AMD) expected in the...
December 22, 2021 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
December 20, 2021 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
November 10, 2021 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates

UBX1325 Phase 2 study in DME currently enrolling, with additional Phase 2 study in AMD planned for 1H22 UNITY to present at invitation-only Eyecelerator innovation conference at AAO SOUTH...
November 09, 2021 07:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease

Patients with diabetic macular edema in higher dose cohorts showed a mean BCVA gain of approximately 10 ETDRS letters sustained through 24 weeks after a single intravitreal injection Patients with...
November 03, 2021 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
October 06, 2021 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right